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Abstract
Background: Immunization of BALB/c mice with a recombinant adenovirus expressing Mycobacterium tuberculosis
(M. tuberculosis) antigen 85A (Ad85A) protects against aerosol challenge with M. tuberculosis only when it is
administered intra-nasally (i.n.). Immunization with Ad85A induces a lung-resident population of activated CD8 T
cells that is antigen dependent, highly activated and mediates protection by early inhibition of M. tuberculosis
growth. In order to determine why the i.n. route is so effective compared to parenteral immunization, we used
microarray analysis to compare gene expression profiles of pulmonary and splenic CD8 T cells after i.n. or intra-
dermal (i.d.) immunization.
Method: Total RNA from CD8 T cells was isolated from lungs or spleens of mice immunized with Ad85A by the i.n.
or i.d. route. The gene profiles generated from each condition were compared. Statistically significant (p ≤ 0.05)
differentially expressed genes were analyzed to determine if they mapped to particular molecular functions,
biological processes or pathways using Gene Ontology and Panther DB mapping tools.
Results: CD8 T cells from lungs of i.n. immunized mice expressed a large number of chemokines chemotactic for
resting and activated T cells as well as activation and survival genes. Lung lymphocytes from i.n. immunized mice
also express the chemokine receptor gene Cxcr6, which is thought to aid long-term retention of antigen-
responding T cells in the lungs. Expression of CXCR6 on CD8 T cells was confirmed by flow cytometry.
Conclusions: Our microarray analysis represents the first ex vivo study comparing gene expression profiles of CD8
T cells isolated from distinct sites after immunization with an adenoviral vector by different routes. It confirms
earlier phenotypic data indicating that lung i.n. cells are more activated than lung i.d. CD8 T cells. The sustained
expression of chemokines and activation genes enables CD8 T cells to remain in the lungs for extended periods
after i.n. immunization. This may account for the early inhibition of M. tuberculosis growth observed in Ad85A i.n.
immunized mice and explain the effectiveness of i.n. compared to parenteral immunization with this viral vector.
Background
It is becoming increasingly apparent that when T cells
are essential for protective immunity the route of vac-
cine delivery may be critical [1-4]. Mice immunized
intra-dermally (i.d.) or intra-muscularly (i.m.) with
recombinant adenovirus expressing Mycobacterium
tuberculosis (M. tuberculosis) antigen 85A (Ad85A)
make a very strong splenic CD8 T cell response, but
show no reduction in the lung mycobacterial burden
after pulmonary challenge with M. tuberculosis com-
pared to naïve mice. In contrast, mice immunized intra-
nasally (i.n.) with Ad85A make much weaker splenic
responses but develop a very strong lung CD8 T cell
response to antigen 85A and are able to reduce signifi-
cantly the mycobacterial burden after M. tuberculosis
challenge [2,5,6]. Regardless of the route of delivery,
immunization with Ad85A generates a predominantly
CD8 T cell response in BALB/c mice, characterized by
production of IFNg, TNF and some IL-2. We and others
have shown that in this model the localization and con-
tinued presence of 85A-specific cells at the site of
pathogen entry is dependent on the presence of antigen
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Furthermore, M. tuberculosis growth in the lungs is
inhibited during the first 8 days after infection in
Ad85A i.n. immunized mice. This is in contrast to mice
immunized parenterally with BCG, in which the kinetics
of M. tuberculosis growth are unchanged compared to
naïve mice up to day 14 [5]. Thus it appears that the
presence of activated effector T cells in the lungs plays a
role in the protective immunity induced by Ad85A i.n.
immunization. Nevertheless, these data do not satisfac-
torily explain why mice immunized i.d., which make a
strong systemic immune response to 85A, fail to show
any protection against pulmonary M. tuberculosis infec-
tion or dissemination of M. tuberculosis to the spleen.
We therefore sought to determine whether there are
any differences in gene expression in the CD8 T cells
induced by Ad85A i.d. or i.n. immunization that might
explain the difference in protection. Microarray analysis
was performed on RNA from lung and spleen CD8 T
cells from Ad85A i.n. or i.d. immunized mice. The tran-
scriptional profiles of lung CD8 T cells from Ad85A i.n.
immunized mice show higher expression of chemokines,
activation markers and tissue homing receptors, which
m a ye n a b l et h e mt or e s i d ei nt h el u n gf o re x t e n d e d
periods.
Methods
Animals and immunization
All experiments were performed with 6-8 week old
female BALB/c mice (Harlan Orlac, Blackthorn, UK),
were approved by the animal use ethical committee of
Oxford University and fully complied with the relevant
Home Office guidelines. Mice were immunized with a
recombinant replication deficient adenovirus serotype 5
containing the 85A antigen from M. tuberculosis
(Ad85A) [5]. For intra-dermal (i.d.) immunization mice
were anaesthetized and injected with 25 μl in each ear,
containing a total of 2 × 10
9 virus particles (v.p.) of
Ad85A per mouse and for i.n. immunization allowed
slowly to inhale 50 μlo f2×1 0
9 v.p. of Ad85A.
Enrichment of CD8 T cells from lung and spleen and RNA
extraction
Lungs were perfused with PBS, cut into small pieces and
digested with 0.7 mg/ml collagenase type I (Sigma,
Poole, UK) and 30 μg/ml DNase I (Sigma) for 45 min at
37°C. Lung fragments were then crushed through a cell
strainer using a 5 ml syringe plunger, washed, layered
over Lympholyte (Cederlane, Ontario, Canada) and cen-
trifuged. Interface cells were washed and CD8 T cells
selected by adding CD8 Microbeads (Miltenyi Biotec,
Bisley, UK), followed by positive selection on MACS
columns. The isolated cells were placed in Trizol and
total RNA extracted using chloroform and isopropanol
followed by cleanup on Qiagen RNeasy MinElute spin
columns (Qiagen, Crawley, UK). RNA was quantitated
and purity was determined on a Nanodrop (Thermo
Scientific, Loughborough, UK). The spleens were passed
through a cell strainer using a 5 ml syringe plunger,
then red blood cells were lysed using RBC lysis buffer
(Qiagen). The cells were washed and CD8 T cells posi-
tively selected using CD8 Microbeads, followed by
extraction of total RNA as described for the lung sam-
ples. For each immunization route separate pools of 7
lungs or spleens were made and subjected to microarray
analysis.
Microarray analysis
Genome-wide gene expression analysis was performed
using MouseWG6_v2 beadchips (Illumina, Little Ches-
terford, UK) containing 45,200 annotated transcripts.
Briefly, total RNA was amplified and labeled with biotin
during in vitro transcription, then hybridized to the
array, washed, stained with Cy3-Streptavidin complex
and subsequently scanned. QC and gene detection was
performed using GenomeStudio (Illumina). For each
condition, RNA samples obtained from 3 independent
experiments were tested separately to generate triplicate
sets of data per condition. The data files are available at
t h eG e n eE x p r e s s i o nO m n i b u sd a t ar e p o s i t o r y :
GSE23713. The genes detected from each condition
were compared against others to determine statistically
significant (p ≤ 0.05) fold changes in expression. The
lists of differentially expressed genes and their corre-
sponding fold change values were subsequently analyzed
using Gene Ontology [9] and Panther DB websites [10]
to determine whether the changes mapped to particular
molecular functions, biological processes or pathways.
Aerosol M. tuberculosis challenge
Four weeks after the Ad85A immunization, mice were
challenged by aerosol with M. tuberculosis (Erdman
strain, kindly provided by Dr Amy Yang, CBER/FDA)
using a modified Henderson apparatus [11]. Deposition
in the lungs was measured 24 h after M. tuberculosis
challenge and was ~200 CFU per lung. Mice were
sacrificed at 6 weeks after M. tuberculosis challenge.
Spleens and lungs were homogenized and the bacterial
load was determined by plating 10-fold serial dilutions
of tissue homogenates on Middlebrook 7H11 agar
plates (E & O Laboratories Ltd, Bonnybridge, UK).
Colonies were counted after 3-4 weeks of incubation at
37°C in 5% CO2.
Flow cytometry
Lung cells were cultured in DMEM supplemented with
10% heat-inactivated FBS, L-glutamine, penicillin and
streptomycin. Cells were stimulated with a mix of 3
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encoding dominant and subdominant CD8 and domi-
nant CD4 epitopes of antigen 85A [5]. Each peptide was
at a final concentration of 2 μg/ml during the stimula-
tion. After 1 hour at 37°C Golgi Plug (BD Biosciences,
Oxford, UK) was added according to the manufacturer’s
instructions and cells were incubated for an additional 5
hours before intracellular cytokine staining.
Cells were washed and incubated with CD16/CD32
mAB to block Fc binding. Subsequently the cells were
stained for CD4 (RM4-5), IFNg (XMG1.2), IL-2 (JES6-
5H4), TNF (MP6-XT22), Lag3 (C9B7W) and Ly 6A
(D7) (eBioscience, Hatfield, UK), CXCR6 antibody
(221002) (R&D Systems, Abingdon, UK), and CD8 (53-
6.7) (BD Bioscience). For intracellular cytokine staining,
cells were stained using the BD Cytofix/Cytoperm kit
according to the manufacturer’s instructions. Cells were
fixed with PBS 1% paraformaldehyde, run on a LSRII
(BD Biosciences) and analyzed using FlowJo software
(Tree Star Inc, Ashland, Oregon, USA).
Detection of chemokines by ELISA
Lung lymphocytes were isolated as described above and
incubated in RPMI+10% FCS at 37°C for 6 hours with-
out stimulation. The supernatant was collected and
stored at -80°C until analysis. CXCL16 (R&D Systems)
ELISA and Multi-Analyte ELISArray for Mouse Com-
mon Chemokines (SABiosciences, Frederick, MD, USA)
kits were employed.
Results
Immunization with Ad85A i.n. or i.d
In agreement with previous reports [2,5,6], mice immu-
nized with Ad85A i.n. developed a strong 85A-specific
T cell response in the lung and a much weaker splenic
response, while Ad85A i.d. immunized mice make a
stronger spleen and weaker lung response (Figure 1).
Ad85A i.n. mice reduced the lung mycobacterial load by
~1 log compared to naïve mice (Figure 2A), a protective
effect comparable to BCG [5,12], while Ad85A i.d.
immunization did not reduce the bacterial load either in
the lungs or spleen (Figure 2B). The responses induced
b yA d 8 5 Ai nB A L B / cm i c ea r ed o m i n a t e db yC D 8T
cells (Figure 1). In C57BL/6 mice Ad85A immunization
induces a CD4 response and no consistent statistically
significant protection against pulmonary M. tuberculosis
challenge is obtained. However in BALB/c mice it has
been demonstrated that antigen-specific CD8 T cells in
the lung are critical for protection against pulmonary
infection with M. tuberculosis in this immunization
model [7,13]. Therefore we wished to determine if CD8
T cells from the lungs and spleens of BALB/c mice dif-
fered. Mice were immunized i.n. or i.d. with Ad85A and
CD8 T cells isolated from the lungs (lung i.n. or i.d.) or
spleens (spleen i.n. or i.d.) 3 weeks post-immunization,
close to the peak of the cytokine response [5]. Purifica-
tion by positive selection resulted in CD8 T cell popula-
tions which were 80-86% pure from lungs and 86-90%
pure from spleens. Total RNA was prepared from cells
isolated in 3 independent experiments, amplified and
global genome analysis was performed using Illumina
microarrays. The expression profiles of spleen and lung
CD8 T cells were compared. Transcripts with ≥ 2f o l d
difference in signal intensity with a p-value of ≤ 0.05
were considered for further analysis, apart from the
comparison between spleen i.n. and spleen i.d. where
transcripts with ≥ 1.5 fold difference were considered.
Comparison of gene expression between lung i.n. and
spleen i.d
We compared the expression profiles of lung i.n.
(protective regime) with spleen i.d. (non-protective
regime) CD8 T cells. 550 transcripts were found to be
differentially expressed (Additional file 1), with 186 tran-
s c r i p t sm o r eh i g h l ye x p r e ssed by the lung i.n. sample
and 364 transcripts by the spleen i.d. samples. Gene
Ontology mapping of the 550 differentially expressed
genes indicated that a large proportion were related to
expression of extracellular proteins or involved in
responses to extracellular stimuli or immune system
processes (Figure 3A).
In agreement with this, when the list of differentially
expressed genes was classified according to function
using Panther analysis, 105 of the 550 differentially
e x p r e s s e dt r a n s c r i p t sw e r ef o u n dt ob ei n v o l v e di n
immune-related processes (Table 1). Of these 105 tran-
scripts, 64 were more highly expressed in spleen i.d.
samples, many of which were classified as related to
either inflammation, complement- or ligand-mediated
signaling processes, signal transduction or other host
immune responses (Table 1). Additionally, higher levels
of transcripts for antimicrobial molecules such as cathe-
licidin (Camp) (section XI Table 1) and lactotransferrin
(Ltf) (section XII Table 1) were detected. Human cathe-
licidin has been reported to inactivate adenoviruses [14]
and lactotransferrin to mediate entry of adenovirus sub-
type 5 virus into cells [15]. The only chemokine-related
genes more highly expressed in spleen i.d. samples were
Ccl24, along with its cognate receptor Ccr3. In addition
to processes associated with immunity, the Panther pro-
gram also predicted that many genes more highly
expressed in spleen i.d. samples play a role in numerous
and diverse non-immune associated processes such as
blood circulation and gas exchange, blood clotting, por-
phyrin metabolism, sensory perception, proteolysis and
cell structure and motility (data not shown).
In contrast, of the 41 genes more highly expressed in
lung i.n. samples, 8 are chemokines, namely Xcl1, Cxcl1,
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Figure 1 Cytokine responses of T cells to antigen 85A. BALB/c mice were immunized with Ad85A i.d. or i.n. Lung and splenic lymphocytes
were isolated 3 weeks post-immunization and stimulated with the dominant CD4 and dominant and subdominant CD8 peptides. The
percentage of cells expressing IFNg, TNF and IL-2 in (A) splenic CD8, (B) lung CD8, (C) splenic CD4 and (D) lung CD4 T cells as determined by
flow cytometry. The values shown are the mean ± SEM from 3 mice per group and are representative of results obtained from at least 2
independent experiments.
Figure 2 Control of mycobacterial growth after aerosol M. tuberculosis challenge of Ad85A immunized mice.B A L B / cm i c ew e r e
immunized with Ad85A i.d. or i.n. and challenged 4 weeks later with M. tuberculosis by aerosol. Mice were sacrificed 6 weeks later and
mycobacterial burden in the lungs (A) and spleen (B) determined. The results show the log CFU in each mouse and the mean for each group
and are representative of at least 2 independent experiments. The data were analyzed using the Kruskal-Wallis test (p = 0.007 comparing all
groups), followed by Dunn’s multiple comparison test, which returned p-values of < 0.05 for comparisons between naïve vs. i.n. and i.d. vs. i.n.
groups. * indicates p < 0.05 compared to naïve or i.d.
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three, Oas12, Oas2 and Gbp1, are interferon-stimulated
genes (sections I and II Table 1). Chemokines such as
Xcl1, Ccl1, Ccl2, Ccl7 and Ccl8 are responsible for
recruitment of activated T cells into tissues (IUPHR
database: http://www.iuphar-db.org/DATABASE/Famil-
yIntroductionForward?familyId=14). Because selection of
genes in Panther is dependent on what has been
curated, some genes that were differentially expressed
and clearly related to immune processes but not classi-
fied by Panther, were added to Table 1 (section XII).
Two other chemokine genes, Cxcl12 and Cxcl13,w e r e
preferentially expressed in lung i.n. samples (section XII
Table 1), as was the T cell activation/memory marker
Ly6a. Genes involved in lymphocyte effector function
such as Ifngr2 (IFNg receptor 2) and the TNF-stimulated
gene TNFsf13b (BAFF) [16] were also upregulated in
lung i.n. These data suggests that Ad85A i.n. immuniza-
tion establishes an activation program in lung CD8
T cells differing from that found in the spleen of Ad85A
i.d. immunized mice.
It should be noted that some of the differences in
gene expression shown in Table 1 are most likely due to
contaminating cell types, which are a particular problem
in the lung i.n. samples. For example, secretoglobin
(Scgbla1) and surfactant associated protein D (Spd)
show high fold-differences in the comparison but these
proteins are predominantly produced by pulmonary
Clara cells [17] or type II cells [18] and not T cells. Not
surprisingly, these genes do not show differences in
expression between lung i.n. and lung i.d. samples
(below), which presumably have approximately equal
contamination with non-lymphoid lung cells.
Comparison of gene expression between lung i.n. and
lung i.d
When lung i.n. (protective) were compared to lung i.d.
(non-protective) CD8 T cells, we found a total of 245
differentially expressed genes (Additional file 2). Almost
all the differentially expressed genes were more highly
expressed in the lung i.n. samples. Gene Ontology analy-
sis indicated that many of the highly expressed tran-
scripts in the lung i.n. cells were related to immune
processes (Figure 3B). Panther classification indicated
that 86 of the 245 genes play a role in immune-related
processes. Of these, 16 were classified as cytokine- and
chemokine-mediated immunity and signaling genes, 11
as interferon-stimulated genes, 23 as T cell activation
genes and 7 as apoptosis-related (Table 1). As before, a
further 14 immunologically-related genes which were
not curated by Panther were added to the table (section
XII Table 1).
The lung i.n. sample expressed higher levels of the tis-
sue-homing CC chemokines Ccl1, Ccl2, Ccl3, Ccl4, Ccl5,
Ccl7, Ccl8 and CXC chemokines Xcl1, Cxcl2, Cxcl9 and
Cxcl16, which are able to recruit resting and activated T
cells as well as other immune cells. Cxcr6,w h i c hm a y
aid in localization of activated T cells to non-lymphoid
tissue [19-21], was also preferentially up-regulated in the
lung i.n. samples. Flow cytometric analysis indicated that
this was detectable on the surface of lung i.n. CD8 T
cells but was present on very few CD8 T cells from lung
i.d. immunized animals, confirming the differential
expression detected by microarray analysis (Figure 4A).
Similarly, increased expression of Lag3 protein was
detected on the surface of a subset of lung i.n. CD8 T
cells (Figure 4B). Measurement of chemokine produc-
tion by ex vivo lung lymphocytes isolated from i.n. and
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Figure 3 Gene Ontology analysis of differentially expressed
genes in CD8 T cells. (A) Spleen i.d. vs lung i.n., based on 550
differentially expressed transcripts and (B) lung i.n. vs lung i.d. based on
245 differentially expressed transcripts (>2 fold difference, p < 0.05).
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Page 5 of 15Table 1 Differentially expressed host genes which mapped to immune related responses
Annotation Name Accession Fold Difference
I Cytokine and chemokine-mediated immunity and signalling lung i.n. vs
spleen i.d.
lung i.n.vs
lung i.d.
CD40 antigen Cd40 NM_170702.2 3.0
Chemokine (C motif) ligand 1 Xcl1 NM_008510.1 4.0 8.0
Chemokine (C-C motif) ligand 1 Ccl1 NM_011329.1 9.7 6.7
Chemokine (C-C motif) ligand 2 Ccl2 NM_011333.1 3.2 2.2
Chemokine (C-C motif) ligand 3 Ccl3 NM_011337.1 4.3
Chemokine (C-C motif) ligand 4 Ccl4 NM_013652.1 7.4
Chemokine (C-C motif) ligand 5 Ccl5 NM_013653.1 3.4
Chemokine (C-C motif) ligand 7 Ccl7 NM_013654 17.9 6.9
Chemokine (C-C motif) ligand 8 Ccl8 NM_021443.1 10.7 4.3
Chemokine (C-C motif) ligand 12 Ccl12 NM_011331 2.7
Chemokine (C-C motif) ligand 24 Ccl24 NM_019577.2 -4.3
Chemokine (C-X-C motif) ligand 1 Cxcl1 NM_008176.1 2.9
Chemokine (C-X-C motif) ligand 2 Cxcl2 NM_009140 2.4
Chemokine (C-X-C motif) ligand 9 Cxcl9 NM_008599 12.6
Chemokine (C-C motif) receptor 3 Ccr3 NM_009914.2 -2.1
Chemokine (C-X-C motif) receptor 6 Cxcr6 NM_030712.1 5.3
Colony stimulating factor 1 (macrophage) Csf1 NM_007778.1 2.1
Colony stimulating factor 3 receptor (granulocyte) Csf3r NM_007782.1 -2.1
Cytokine inducible SH2-containing protein Cish NM_009895.2 4.7 4.5
Interferon gamma Ifng NM_008337.1 5.2
Interferon gamma receptor 2 Ifngr2 NM_008338.2 3.2
Interleukin 18 Il18 NM_008360.1 -4.3
Lymphocyte-activation gene 3 Lag3 NM_008479.1 2.8 5.0
Protein tyrosine phosphatase, non-receptor type 6 Hcph NM_013545.1 2.0
Signal-regulatory protein alpha Ptp4a3 NM_008975.2 -2.1
Transferrin Trf NM_133977.1 -8.8
Tumor necrosis factor Tnf NM_013693 2.6
II Inflammation mediated pathway
Cyclin-dependent kinase inhibitor 1A (P21) Cdkn1a NM_007669.2 2.2
Gardner-Rasheed feline sarcoma viral (Fgr) oncogene homolog Fgr NM_010208 -3.5
Integrin alpha 9 Itga9 NM_133721.1 -3.0
Procollagen, type XIV, alpha 1 Col14a1 AK052963 -3.4
Prostaglandin-endoperoxide synthase 1 Ptgs1 NM_008969.1 -7.0
Vav2 oncogene Vav2 NM_009500.1 -3.7
III Interferon-stimulated genes
2’-5’ oligoadenylate synthetase-like 2 Oasl2 NM_011854.1 4.0 3.3
2’-5’ oligoadenylate synthetase 1G Oas1g NM_011852.2 3.2
Guanylate nucleotide binding protein 1 Gbp1 NM_010259.1 2.2 5.5
Guanylate nucleotide binding protein 2 Gbp2 NM_010260.1 4.4
Guanylate nucleotide binding protein 4 Gbp4 NM_018734.2 3.2
Interferon activated gene 202B Ifi202b NM_008327.1 2.4
Interferon-induced protein with tetratricopeptide repeats 2 Ifit2 NM_008332.2 2.0
Interferon-induced protein with tetratricopeptide repeats 3 Ifit3 NM_010501.1 3.9
Interferon regulatory factor 8 Icsbp1 NM_008320.2 3.2
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Signal transducer and activator of transcription 1 Stat1 NM_009283 3.0
SLAM family member 8 Slamf8 XM_129596.2 5.0
IV T cell activation
Beta-2 microglobulin B2m NM_009735.2 2.3
Cathepsin S Ctss NM_021281.1 3.0
CD74 antigen (invariant polypeptide of major histocompatibility complex,
class II antigen-associated)
li BC003476 5.6
CD86 antigen Cd86 NM_019388.2 -2.3 2.5
CD274 antigen Pdcd1lg1 NM_021893.2 2.5 3.8
Cytotoxic T-lymphocyte-associated protein 4 Ctla4 NM_009843.2 3.9
Histocompatibility 2, Q region locus 6 H2-Q6 NM_207648 3.0
Interferon gamma inducible protein 30 Ifi30 NM_023065.2 2.5
Histocompatibility 2, class II antigen A, beta 1 H2-Ab1 NM_207105.1 7.7
Histocompatibility 2, D region locus 1 H2-D1 NM_010380.2 3.0
Histocompatibility 2, class II, locus Dma H2-DMa NM_010386 3.9
Histocompatibility 2, class II, locus Mb1 H2-DMb1 NM_010387.2 5.8
Histocompatibility 2, class II, locus Mb2 H2-DMb2 NM_010388 5.5
Histocompatibility 2, class II antigen E alpha H2-Ea NM_010381.2 6.5
Histocompatibility 2, class II antigen E beta H2-Eb1 NM_010382.1 7.9
Histocompatibility 2, K1, K region H2-K1 NM_001001892.1 3.0
Histocompatibility 2, M region locus 3 H2-M3 NM_013819.1 2.6
Histocompatibility 2, Q region locus 2 H2-Q2 NM_010392.2 2.7
Histocompatibility 2, Q region locus 5 H2-Q5 NM_010393.1 2.9
Histocompatibility 2, T region locus 10 H2-T10 NM_010395.5 2.5
Histocompatibility 2, T region locus 23 H2-T23 NM_010398.1 2.9
Histocompatibility 2, T region locus 9 H2-T9 NM_010399 3.1
Peroxiredoxin 5 Prdx5 NM_012021 2.2
V Other ligand-mediated signalling
Calcitonin/calcitonin-related polypeptide, alpha Calca NM_007587 2.0
E2F transcription factor 2 E2f2 NM_177733.2 -3.4
Endothelin 1 Edn1 NM_010104.2 2.1
Endothelial differentiation, sphingolipid G-protein-coupled receptor, 5 Edg5 NM_010333 2.1
FMS-like tyrosine kinase 1 Flt1 NM_010228.2 3.9
Granulin Grn NM_008175.2 2.8
Mannose-6-phosphate receptor, cation dependent M6pr NM_010749.4 2.2
Paired-Ig-like receptor A1 Pira1 NM_011087.1 -2.1
Paired-Ig-like receptor A11 Pira11 NM_011088.1 -2.1
Paired-Ig-like receptor A3 Pira3 NM_011090.1 -3.8
Paired-Ig-like receptor A4 Pira4 NM_011091.1 -2.4
Peroxisome proliferator activated receptor gamma Pparg NM_011146.1 -2.7
Pre-B-cell colony-enhancing factor 1 Pbef1 NM_021524.1 2.7
Secretoglobin, family 1A, member 1 (uteroglobin) Scgbla1 NM_011681.1 40.0
Solute carrier family 1 (glial high affinity glutamate transporter), member 3 Slcla3 NM_148938.2 -2.5
Spermine oxidase Smox NM_145533.1 -2.7
Vascular endothelial growth factor A Vegfa NM_009505.2 2.5
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VI Complement-mediated
Complement component 1, q subcomponent, alpha polypeptide C1qa NM_007572 -3.6
Complement component 1, q subcomponent, beta polypeptide C1qb NM_009777.1 -4.5 3.8
Complement component 1, q subcomponent, C chain C1qg NM_007574.1 -4.3
Complement component 2 (within H-2S) C2 NM_013484.1 -3.3
Complement component 3 C3 NM_009778.1 4.2
Complement component 4A (Rodgers blood group) Slp NM_011413 2.3
Complement component 6 C6 NM_016704.1 -2.6
Complement factor B H2-Bf NM_008198.1 11.5 6.5
Complement factor properdin Pfc XM_135820.3 -10.3
Four and a half LIM domains 1 Fhl1 NM_010211.1 2.3
VII Apoptosis
B-cell leukemia/lymphoma 2 related protein A1b Bcl2a1b NM_007534 2.5
B-cell leukemia/lymphoma 2 related protein A1d Bcl2a1d NM_007536 2.7
Caspase 1 Casp1 NM_009807.1 4.0
Caspase 4, apoptosis-related cysteine peptidase Casp4 NM_007609.1 2.4
Epithelial membrane protein 3 Emp3 NM_010129.1 2.3
Lectin, galactose binding, soluble 1 Lgals1 NM_008495.1 4.0
Thioredoxin 1 Txn1 NM_011660.3 2.1
VIII Signal transduction
AXL receptor tyrosine kinase Axl NM_009465.2 -6.4
C-mer proto-oncogene tyrosine kinase Mertk NM_008587 -3.7
C-type lectin domain family 4, member a1 BC049354 XM_194289.2 -3.0
C-type lectin domain family 4, member b1 Clec4b1 NM_027218.1 -3.9
C-type lectin domain family 4, member a3 Clec4a3 NM_153197.3 -2.1
CD63 antigen Cd63 NM_007653.1 3.3
CD81 antigen Cd81 NM_133655.1 -4.6
CD93 antigen C1qr1 NM_010740.1 3.7
CD207 antigen Cd207 NM_144943.2 -2.2
Chemokine (C-X-C motif) ligand 15 Cxcl15 NM_011339.1 5.0
Colony stimulating factor 1 receptor Csf1r NM_007779.1 -9.5
Integrin beta 5 Itgb5 NM_010580 -3.4
Neutrophilic granule protein Ngp NM_008694.1 -8.9
Plasminogen activator, urokinase Plau NM_008873.2 2.2
S100 calcium binding protein A9 (calgranulin B) S100a9 NM_009114.1 -4.2
Thrombomodulin Thbd NM_009378.1 4.6
IX Other cell communication
Cadherin 1 Cdh1 NM_009864.1 4.8 3.2
Hematological and neurological expressed sequence 1 Hn1 NM_008258.1 2.3
Intercellular adhesion molecule Icam1 NM_010493.2 2.3
Lectin, galactoside-binding, soluble, 3 binding protein Lgals3bp NM_011150.1 4.0
Proteolipid protein 2 Plp2 NM_019755.2 2.5
Purine-nucleoside phosphorylase Pnp NM_013632.2 3.2
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Page 8 of 15Table 1 Differentially expressed host genes which mapped to immune related responses (Continued)
X Natural killer cell-mediated immunity
Fc fragment of IgG, low affinity IIIa, receptor Fcrl3 NM_144559.1 3.8
Killer cell lectin-like receptor subfamily C, member 1 Klrc1 NM_010652 3.8
Killer cell lectin-like receptor subfamily K, member 1 Klrk1 NM_033078.2 2.0
Natural killer cell group 7 sequence Nkg7 NM_024253.3 3.7
XI Other host immune responses
Allograft inflammatory factor 1 Aif1 NM_019467.2 -2.8 2.7
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 Abcc3 XM_358306.1 -10.6
Carboxylesterase 3 Ces3 NM_053200.1 2.9
Catalase Cat NM_009804.1 -2.3
Cathelicidin antimicrobial peptide Camp NM_009921.1 -18.3
Cathepsin E Ctse NM_007799 -2.3
CD59a antigen Cd59a NM_007652.2 -3.0
CD93 antigen C1qr1 NM_010740.1 3.7
CD163 antigen Cd163 NM_053094.1 -10.1
CD244 natural killer cell receptor 2B4 Cd244 NM_018729 -3.3
Coagulation factor X F10 NM_007972.2 2.6
Fc receptor, IgG, alpha chain transporter Fcgrt NM_010189.1 -4.8
Glutathione peroxidase 1 Gpx1 NM_008160.1 -2.7
Glutathione peroxidase 3 Gpx3 NM_008161.1 -2.0
Glutathione S-transferase, mu 2 Gstm2 NM_008183.2 5.0
Glutathione S-transferase omega 1 Gsto1 NM_010362.1 -2.1
Guanine nucleotide binding protein (G protein), gamma 2 subunit Gng2 NM_010315.2 2.9
Guanine nucleotide binding protein (G protein), gamma 10 Gng10 NM_025277 2.4
Hemochromatosis Hfe NM_010424.2 -5.3
Immunoresponsive gene 1 Irg1 XM_127883 2.8
Interferon, alpha-inducible protein 27 2310061N23Rik NM_029803 3.9
Interferon induced transmembrane protein 2 Ifitm2 NM_030694.1 -2.0
Interferon induced transmembrane protein 6 Ifitm6 XM_133956.3 -5.0
Kruppel-like factor 6 Copeb NM_011803.1 2.5
Lipocalin 2 Lcn2 NM_008491.1 -5.1
LPS-induced TN factor Litaf NM_019980 2.6
Lymphocyte antigen 96 Ly96 NM_016923.1 -2.2
Lysozyme Lyzs NM_017372 2.5
Mannose receptor, C type 1 Mrc1 NM_008625.1 -7.6
Membrane-associated ring finger (C3HC4) 8 Mir NM_027920.3 -2.2
Myeloperoxidase Mpo NM_010824.1 -3.3
Peptidoglycan recognition protein 1 Pglyrp1 NM_009402.1 -2.5
Peripheral myelin protein Pmp22 NM_008885.1 3.5
Peroxidasin homolog (Drosophila) 2310075M15Rik XM_283052 2.0
Peroxiredoxin 2 Prdx2 NM_011563.2 -3.5
Peroxiredoxin 5 Prdx5 NM_012021 2.4
Phytoceramidase, alkaline Phca NM_025408.1 -2.1
Prosaposin Psap NM_011179 -2.1 2.3
Regulator of G-protein signaling 1 Rgs1 NM_016846.2 4.8
S100 calcium binding protein A4 S100a4 NM_011311.1 4.6
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Page 9 of 15i.d. immunized mice at 3 weeks post-immunization con-
firmed increased production of CCL2, CCL3, CCL4,
CCL5, CXCL9 and CXCL16 (Table 2).
Compared to lung i.d. cells, lung i.n. CD8 T cells
exhibited a strong anti-viral response, displaying higher
levels of interferon-stimulated genes such as Stat1,
Oasl2, Gbp1 and Gbp2. Pdcd1lg, Ifit130, Wars (trypto-
phanyl-tRNA synthetase) and diverse MHC Class II
genes, indicating sustained activation of the IFNg path-
way. Additionally, high levels of activation markers such
as Ly6a, Ly6c and Ctla-4, together with the antigen pro-
cessing protease cathepsin S (Ctss), implied that there
was a larger proportion of highly differentiated effector
or memory CD8 T cells in the lung i.n. samples [22].
Increased expression of Ly6A on lung i.n. CD8 T cells
was confirmed by flow cytometry (Figure 4C).
Serine peptidase inhibitor clade A member 3G, also
known as Serpina3g or Spi2A exhibited the highest (14-
fold) difference in expression in lung i.n. compared to
lung i.d. samples. Serpina3g is highly expressed in effector
and memory CD8 T cell populations [23]. During the con-
traction phase of immune responses, it protects expanded
antigen-specific CD8 effectors from programmed cell
death by inactivating lysosomal proteases [24], thereby
regulating the contraction phase and ensuring that a high
frequency of antigen-specific T cells remain to develop
into memory cells [23]. The detection of high levels of Ser-
pina3g transcript in lung i.n. samples suggests the pre-
sence of a pool of effector or memory T cells substantially
larger than in the lung i.d. group, as confirmed by the fre-
quency of antigen-specific cells (Figure 1).
Intriguingly, several inhibitory and activating mole-
cules were also highly expressed in the lung i.n. samples,
notably Klrc1 which is also known as NKG2A. NKG2A
expression has been proposed as a marker for prolifera-
tive potential of CD8 memory T cells and may down-
Table 1 Differentially expressed host genes which mapped to immune related responses (Continued)
S100 calcium binding protein A8 (calgranulin A) S100a8 NM_013650.1 -4.4
SAM domain and HD domain, 1 Samhd1 BC067198 2.8
Selenoprotein P, plasma, 1 Sepp1 NM_009155.3 -2.4
Serum amyloid A 3 Saa3 NM_011315 4.5
Solute carrier family 11 (proton-coupled divalent metal ion transporters),
member 1
Slc11a1 NM_013612.1 -2.2
Superoxide dismutase 2, mitochondrial Sod2 NM_013671.2 2.9
Surfactant associated protein A1 Sftpa1 NM_023134.3 2.5
Surfactant associated protein D Sftpd NM_009160.1 10.4
XII Genes mentioned in text but not categorized by Panther
Chemokine (C-X-C motif) ligand 12 Cxcl12 NM_013655.2 4.0
Chemokine (C-X-C motif) ligand 13 Cxcl13 NM_018866.1 2.1
Chemokine (C-X-C motif) ligand 16 Cxcl16 NM_023158 4.1
Expressed sequence AA467197 AA467197 NM_001004174.1 8.8
Lymphocyte antigen 6 complex, locus A Ly6a NM_010738.2 5.8 4.7
Immunity-related GTPase family, M Irgm NM_008326.1 2.8
Lymphocyte antigen 6 complex, locus C Ly6c NM_010741 3.0
Mus musculus lactotransferrin Ltf NM_08522.2 -16.8
Proteasome (prosome, macropain) subunit, beta type 9 Psmb9 NM_013585.1 2.9
Proteasome (prosome, macropain) subunit, beta type 8 Psmb8 NM_010724 3.2
Proteasome (prosome, macropain) subunit, beta type 10 Psmb10 NM_013640.1 2.4
Serine (or cysteine) peptidase inhibitor, clade A, member 3G Serpina3g NM_009251.1 14.8
Three prime repair exonuclease 1 Trex1 NM_011637.4 2.0
Tryptophanyl-tRNA synthetase Wars NM_011710.2 2.2
Tumor necrosis factor (ligand) superfamily, member 13b Tnfsf13b NM_033622 3.1 3.0
Ubiquitin D (Ubd) Ubd NM_023137.2 4.2
Ubiquitin specific peptidase 18 Usp18 NM_011909.1 2.6
Expression was analyzed using Genome Studio and classified by immune function through Panther Immune Processes. Genes not classified by Panther but
clearly related to immune processes were added manually (section XII). All processes were analyzed statistically with a p-value ≤ 0.05.
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Page 10 of 15regulate effector activity as a means to limit immuno-
pathology [25,26]. Interestingly another gene showing a
high fold difference between lung i.n. and lung i.d. sam-
ples is AA467197 (Nmes1), which was recently reported
to encode a microRNA and may act to dampen down
excessive inflammation [27]. In contrast Klrk1 has been
reported to function as a co-stimulatory receptor for
activated CD8 T cells [28,29]. Along with Serpina3g,
these genes share important roles in regulating CD8
effector function and survival.
Several MHC class II molecules showed higher expres-
sion in the lung i.n. samples. As it has been previously
reported that surface expression of Class II is not detect-
able on mouse T cells [30], a possible explanation for the
presence of the transcripts could be co-purification of
CD8+ dendritic cells or expression of Class II on contam-
inating non-T cells. However, microarray datasets of
mature and activated murine C57BL/6 CD8 T cells
http://refdic.rcai.riken.jp/welcome.cgi, isolated to 99%
purity by cell sorting, also show up-regulation of MHC
Class II transcripts, suggesting that murine CD8 T cells
can express MHC Class II mRNA.
In summary, the comparison of lung i.n. and lung i.d.
samples demonstrated a striking relative increase in
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Figure 4 CXCR6 expression on CD8 T cells from lungs of Ad85A immunized mice. BALB/c mice were immunized i.d. or i.n. with Ad85A. At
3 weeks post-immunization, lung lymphocytes were isolated and the percentage of CD8 T cells expressing CXCR6 was determined by flow
cytometry. (A) Representative FACS plots of CD8
+ gated cells showing CD8
+CXCR6
+ cells in lungs of i.d. and i.n. immunized mice. The bar chart
shows the mean ± SEM from 3 independent experiments with 3 mice per group. (B) Representative FACS plots of CD8
+ gated cells showing
CD8
+Lag3
+ cells in lungs of i.d. and i.n. immunized mice 8-12 weeks previously. The bar chart shows the mean ± SEM of 3 i.d. and 5 i.n.
immunized mice. (C) A representative histogram showing the expression of Ly6a on lung CD8 T cells. The bar chart shows the mean
fluorescence intensity (MFI) ± SEM of 3 i.d. and 5 i.n. immunized mice. * indicates p < 0.05 by Mann-Whitney test.
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Page 11 of 15expression of chemokine genes involved in migration
and retention of cells as well as in genes related to acti-
vation, regulation and survival of memory T cells.
Comparison of gene expression between spleen i.n. and
spleen i.d
As very few genes showed differential expression when
spleen i.n. and i.d. samples were compared, we analyzed
genes exhibiting fold differences ≥1.5 (Additional file 3).
Even so, only 9 genes were differentially expressed and
fold differences between only 1.5 and 2.8 were observed.
Eight of the transcripts, Klrc1, Gzmk (granzyme K), Ltf,
Amy2, 111001Rik, S100a6, Kcnk5 (potassium channel
subfamily k, member 5) and Klrk1 (killer cell lectin-like
receptor, subfamily K, member 1) were higher in spleen
i.d. samples, while the single transcript more highly
expressed in spleen i.n. was IGKV1-88_AJ231206_Ig_-
kappa_variable_1-88_289, possibly an IgG kappa chain.
Higher levels of transcripts of granzyme K, killer cell
activators Klrc1, Klrk1, and the inflammation marker
S100a6 suggested that spleen i.d. were more activated
than spleen i.n. CD8 T cells. The few differences in
gene expression between the splenic i.n. and i.d. samples
m a yb eb e c a u s et h ea n t i g e n8 5 A - s p e c i f i cc e l l si nt h e
spleen represent a small proportion of the whole splenic
CD8 population (Figure 1) or because the spleen, as a
major hub of lymphoid traffic, may reflect irrelevant
ongoing systemic immune responses at the time of
sampling.
Gene expression profile in the lungs after Ad85A i.n.
immunization is distinct from common lung or M.
tuberculosis responses
A common cluster of genes have been identified in mice
and macaques as being non-specifically up-regulated
during acute lung inflammation, irrespective of the type
of stimulus. We compared the profile of differentially
expressed genes between lung i.n. and lung i.d. samples
with the genes which are subject to common up-
regulation following a variety of inflammatory stimuli [31].
Of the 23 genes identified as most highly and commonly
expressed following exposure to a range of pathogens and
environmental insults, only 5 were shared with our lung i.
n./lung i.d. differentially expressed gene set (Figure 5).
These were Ccl2, Ccl4, Ccl7, Cxcl9 and Gbp2.Aw i d e r
group of 50 genes is induced in response to pulmonary
viral or bacterial infections [31]. Prominent among these
are interferon-stimulated genes that are also more highly
expressed in lung i.n. than lung i.d. samples, namely, Aif1,
Casp1, Ccl5, Ifit2, Ly6c, Psmb10, Psmb9, Psmb8, Stat1,
Trex1, Ubd, Usp18 and Wars. While the common
responses described were measured during the acute
phase of infection, less than 8 days post-exposure, i.n.
administration of Ad85A induces expression of a subset of
these acute-phase inflammatory molecules three weeks
post-immunization, indicating that the expression profile
i n d u c e dm a yb eau n i q u eh o s tr e s p o n s et oA d 8 5 Ai . n .
immunization.
Unsurprisingly, immunization with Ad85A induced an
expression profile which was quite dissimilar to profiles
generated during aerosol infection with M. tuberculosis
or after immunization with BCG. Genes characteristically
induced by mycobacteria, such as Tlr2/4 and Indo (IDO)
[32], were not highly expressed in lung i.n. samples.
However IFN-signalling pathway genes, such as Icsbp1
and Stat1, as well as genes associated with antiviral
responses, such as Oasl2, Gbp1 and Gbp2,w e r es t r o n g l y
induced in lung i.n. samples, suggesting that virus was
still present in the lungs at 3 weeks post-immunisation
[5,7]. In spite of the differences in gene expression
between mycobacterial and adenoviral immunization,
several genes reported to be involved in M. tuberculosis
clearance, including IFNg and its receptor, Il18, Cxcl13,
Cxcl16, Cxcr6 and Serpina3g are induced by lung i.n.
immunization [32,33]. Thus the immune response to
antigen 85A induced by i.n. immunization with Ad85A
may be favourable for protection against subsequent pul-
monary challenge with M. tuberculosis.
Discussion
It is striking that the route of immunization with the
Ad85A M. tuberculosis subunit vaccine is critical for pro-
tection against pulmonary M. tuberculosis challenge.
Unlike conventional models of M. tuberculosis immunity,
protection induced by Ad85A i.n. immunization in
BALB/c mice is mediated by antigen-specific CD8 T cells
in the lungs with a minimal contribution from CD4 T
cells [7,13]. The antigen 85A-specific lung CD8 cells are
maintained in a highly activated state by the continued
presence of antigen [5] and are not dependent on
Table 2 Production of chemokines by lung lymphocytes
ex vivo after immunization with Ad85A i.d. or i.n.
Absorbance at 450nm (± SD)
Chemokine i.d. i.n.
CCL2 0.89 (±0.427) 1.368 (±0.131)
CCL3 0.334 (±0.066) 0.745 (±0.008)
CCL4 0.278 (±0.011) 0.760 (±0.028)
CCL5 0.386 (±0.098) 1.470 (±0.211)
CXCL9 0.259 (±0.059) 0.566 (±0.034)
Conc (pg/ml)
CXCL16 3.34 (±0.339) 6.095 (±0.977)
Lung lymphocytes were isolated from mice immunized 3 weeks previously
and cultured in RPMI+10% FCS for 6 hours at 37°C without antigen
stimulation. The supernatants were assayed by ELISA for the indicated
chemokines. The table shows the mean absorbance at 450 nm (± standard
deviation (SD)) of 6 mice per group. For CXCL16, the mean concentration of
CXCL16 (pg/ml, ± SD) of 6 mice per group is shown.
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Page 12 of 15recruitment from the periphery [7]. These cells inhibit
M. tuberculosis growth early after pulmonary challenge
[5]. In contrast, although mice immunized i.d. with
Ad85A make a strong systemic CD8 response they are
not protected against M. tuberculosis. Nonetheless sple-
nic immune cells have been shown capable of inhibiting
M. tuberculosis growth when transferred into the lungs
[6]. These findings prompted us to determine whether
differences in gene expression, determined by microarray
analysis, might provide further insight into the protective
mechanisms of lung and splenic CD8 T cells.
Comparison of lung i.n. versus spleen i.d. gene expres-
sion does not show a significant difference in the
expression of Ifng or Tnf or other effector molecules,
suggesting that lung and splenic CD8 T cells have equal
potential to inhibit M. tuberculosis growth, as has been
demonstrated by intra-tracheal transfer of splenic lym-
phocytes [6]. However, lung i.n. cells expressed higher
levels of chemokines such as Ccl1, Ccl2, Ccl7, Ccl8,
Ccl12 and Xcl1 and Cxcl12, suggesting that the main
difference between the two populations is the presence
of chemokines that enhance trafficking and retention of
leukocytes in the lung. When lung i.n. and lung i.d.
samples were compared, several additional chemokines
were more highly expressed in lung i.n. samples, namely
Ccl3, Ccl4, Ccl5, Cxcl9 and Cxcl16. Strikingly the only
cognate chemokine receptor more highly expressed on
lung i.n. than lung i.d. CD8 T cells is Cxcr6,t h er e c e p -
tor for Cxcl16. Cxcr6 has been proposed to be a marker
for retained lung T cells [34]. The presence of CXCR6
protein on a proportion of lung i.n. CD8 T cells was
confirmed by flow cytometry (Figure 4).
Banchereau et al. reported that upon viral infection of
humans, different subsets of chemokines are secreted in
a temporally regulated manner, with CXCL1, CXCL2,
CXCL3 and CXCL16 being secreted first to allow hom-
ing of naïve T cells, then CCL3, CCL4, CCL5, CXCL8,
CXCL9, CXCL10 and CXCL11 to sustain localization of
activated T cells, and finally CCL19, CCL22 and
CXCL13 [35]. In our model, some chemokines reported
to be part of the “1
st and 2
nd waves” of chemokine
expression by DC cells, specifically Xcl1, Cxcl9, Cxcl16,
Ccl1, Ccl2, Ccl3, Ccl4, Ccl5, Ccl7 and Ccl8 are expressed
at increased levels in lung i.n. samples at 3 weeks post-
infection. A possible explanation for the presence of
transcripts involved in activation and recruitment of T
cells at this late time point in lung i.n. and not lung i.d.
s a m p l e si st h ep e r s i s t e n c eo fA d 8 5 Ai nt h el u n g[ 5 ]
inducing sustained expression of IFNg and STAT1
which are able to coordinate expression of numerous
members of the chemokine family [36]. Additionally,
synergism between IFNg and TNF, which are produced
by 85A-specific T cells (Figure 1), may lead to upregula-
tion of a further subset of genes involved in T cell acti-
vation and recruitment, including Irg1,M H CC l a s sI I
molecules and the chemokine genes including Cxcl9
[37]. Sustained expression of these chemokines may
recruit and retain CD8 T cells in the lung so that they
are able to control M. tuberculosis as soon as the myco-
bacteria are present in the lung [5]. In addition, these
chemokines may also recruit other activated immune
cells to the lung, such as macrophages, neutrophils and
NK cells, ensuring that they are present in situ at the
time of infection. Since a hallmark of M. tuberculosis
infection is the very slow initiation of immune responses
and delayed migration of T cells to the lung [38,39],
retention of immune T cells in the lungs, as induced by
persistent antigen stimulation and consequent chemo-
kine production, may be an important reason for the
efficacy of i.n. immunization with Ad85A [5,38,40,41].
Conclusions
Our microarray analysis represents the first ex vivo
study comparing gene expression profiles of CD8 T cells
isolated from distinct sites after immunization with an
adenoviral vector by different routes. It confirms earlier
phenotypic data indicating that lung i.n. cells are more
activated [5] than lung i.d. CD8 T cells. Thus it appears
that the state of activation of the lung i.n. CD8 T cells
is critical for their ability to inhibit M. tuberculosis
growth early after infection. Lung i.n. cells also highly
express many chemokines as well as the CXCR6 recep-
tor. We suggest that continued expression of these
molecules, as a consequence of the persistence of anti-
gen 85A, helps to retain the cells in the lungs. These
two properties may explain why this immunization
regime is effective. An intriguing question for the future
is whether the presence of a population of highly acti-
vated CD8 T cells in the lungs is hazardous for the
Figure 5 The overlap of genes differentially expressed
between lung i.n. and lung i.d., with genes reported to be
related to a common lung inflammatory response. Venn
diagram showing the overlap between genes more highly
expressed by lung i.n. than i.d. cells, with genes reported as
upregulated in lung inflammation [31].
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activating and regulating inflammation, suggesting that
the lungs may be in a stable well-balanced state.
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